Jennifer Klarer
Jen Klarer is a Partner and Head of the Cell & Gene Therapy business unit at The Dedham Group, a Norstella Company. She is interested in contributing to improving and facilitating patient access to emerging medical treatments, particularly in the cell & gene therapy space, to meet rapidly evolving challenges in medicine and improve patient outcomes. She believes in the strength of combining multiple disciplines to develop optimal models and achieve functionally superior solutions. Her extensive work experience in specialty therapeutic commercial strategy, cell & tissue engineering research, and academic knowledge of biomedical engineering, chemistry, mathematics, and physics provide a solid foundation to contribute successfully in the area of pharmaceutical market access strategic planning and advisory.
